Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. - Cai S; Moutal A; Yu J; Chew LA; Isensee J; Chawla R; Gomez K; Luo S; Zhou Y; Chefdeville A; Madura C; Perez-Miller S; et al. (Science translational medicine, 2021)